Persica Strengthens PP353 Case in Vertebrogenic Back Pain
London, UK — September 4, 2026 Persica Pharmaceuticals Limited announced the publication of new antibiotic exposure-response analyses supporting the...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
London, UK — September 4, 2026 Persica Pharmaceuticals Limited announced the publication of new antibiotic exposure-response analyses supporting the...
BERKELEY HEIGHTS, N.J., May 28, 2026 Tonix Pharmaceuticals presented new real-world data at the 2026 American Society of Clinical...
